Radiotherapy and Immunotherapy Combinations for the Treatment of Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (1 September 2021) | Viewed by 6725

Special Issue Editor


E-Mail Website
Guest Editor
Division of Cancer Sciences, Faculty of Biology, School of Medical Sciences, Medicine and Health, University of Manchester, Manchester M13 9PL, UK
Interests: onco-immunology

Special Issue Information

Dear Colleagues,

Radiotherapy (RT) is a principal component of cancer treatment, given to over 50% of patients. In addition to direct cytotoxic activity via the induction of DNA damage, RT can influence the immune response to cancer and recalibrate the tumour microenvironment. Immunogenic changes in response to RT contribute to multiple stages of the cancer immunity cycle, activate the innate immune system and orchestrate priming of tumour-specific immunity. Alternatively, RT can exacerbate immune suppression via the upregulation of inhibitory checkpoints, and recruitment of myeloid cells. The ability of RT to modulate immune responses to cancer provides a clear rationale for combination with immunotherapeutic strategies. An extensive array of preclinical studies support this concept, demonstrating improved local control following combination therapy and highlighting the exciting potential to augment systemic immunity, leading to remission of disease outside of the irradiated field (abscopal responses). In particular, the inclusion of immune checkpoint blockade into the RT regimen has demonstrated considerable efficacy, and combinations of RT and anti-PD1/PD-L1 or CTLA-4 antibodies are currently being evaluated in the clinical arena.

Translating the preclinical potential of RT and immunotherapy combinations into clinical reality requires a greater understanding of the biological mechanisms that underpin the impressive experimental outcomes to date. There remains much uncertainty around the optimal sequence, schedule, dose, fraction and field of RT to use together with immunotherapy. Enhanced understanding of drivers of resistance, as well as identification of biomarkers to better predict which patients will respond to treatment are also required.  

This Special Issue will highlight the role of radiotherapy in modulating the tumour microenvironment and systemic immune response to cancer, the impact of immunotherapy combination on the efficacy of RT and provide a perspective on how RT and immunotherapy combinations can be utilised to enhance patient outcome in the clinic.

Dr. Jamie Honeychurch
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Radiotherapy
  • Immunotherapy
  • Tumour microenvironment
  • Checkpoint blockade
  • Immune suppression
  • Immunogenic cell death

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

18 pages, 6428 KiB  
Article
The Proper Administration Sequence of Radiotherapy and Anti-Vascular Agent—DMXAA Is Essential to Inhibit the Growth of Melanoma Tumors
by Alina Drzyzga, Tomasz Cichoń, Justyna Czapla, Magdalena Jarosz-Biej, Ewelina Pilny, Sybilla Matuszczak, Piotr Wojcieszek, Zbigniew Urbaś and Ryszard Smolarczyk
Cancers 2021, 13(16), 3924; https://doi.org/10.3390/cancers13163924 - 4 Aug 2021
Cited by 11 | Viewed by 2771
Abstract
Vascular disrupting agents (VDAs), such as DMXAA, effectively destroy tumor blood vessels and cause the formation of large areas of necrosis in the central parts of the tumors. However, the use of VDAs is associated with hypoxia activation and residues of rim cells [...] Read more.
Vascular disrupting agents (VDAs), such as DMXAA, effectively destroy tumor blood vessels and cause the formation of large areas of necrosis in the central parts of the tumors. However, the use of VDAs is associated with hypoxia activation and residues of rim cells on the edge of the tumor that are responsible for tumor regrowth. The aim of the study was to combine DMXAA with radiotherapy (brachytherapy) and find the appropriate administration sequence to obtain the maximum synergistic therapeutic effect. We show that the combination in which tumors were irradiated prior to VDAs administration is more effective in murine melanoma growth inhibition than in either of the agents individually or in reverse combination. For the first time, the significance of immune cells’ activation in such a combination is demonstrated. The inhibition of tumor growth is linked to the reduction of tumor blood vessels, the increased infiltration of CD8+ cytotoxic T lymphocytes and NK cells and the polarization of macrophages to the cytotoxic M1 phenotype. The reverse combination of therapeutic agents showed no therapeutic effect and even abolished the effect of DMXAA. The combination of brachytherapy and vascular disrupting agent effectively inhibits the growth of melanoma tumors but requires careful planning of the sequence of administration of the agents. Full article
Show Figures

Graphical abstract

29 pages, 9660 KiB  
Article
Combinations of Radiotherapy with Vaccination and Immune Checkpoint Inhibition Differently Affect Primary and Abscopal Tumor Growth and the Tumor Microenvironment
by Michael Rückert, Lisa Deloch, Benjamin Frey, Eberhard Schlücker, Rainer Fietkau and Udo S. Gaipl
Cancers 2021, 13(4), 714; https://doi.org/10.3390/cancers13040714 - 9 Feb 2021
Cited by 28 | Viewed by 3278
Abstract
Radiotherapy (RT) is known to have immune-modulatory properties. We hypothesized that RT and inactivated whole tumor cell vaccines generated with high hydrostatic pressure (HHP) synergize to retard the tumor growth which can be additionally improved with anti-PD-1 treatment. In abscopal tumor models, we [...] Read more.
Radiotherapy (RT) is known to have immune-modulatory properties. We hypothesized that RT and inactivated whole tumor cell vaccines generated with high hydrostatic pressure (HHP) synergize to retard the tumor growth which can be additionally improved with anti-PD-1 treatment. In abscopal tumor models, we injected mice with B16-F10 melanoma or TS/A mammary tumors. To evaluate the efficiency of RT in combination with HHP vaccines, we locally irradiated only one tumor with 2 × 8 Gy or 3 × 8 Gy. HHP vaccines further retarded the growth of locally irradiated (2 × 8 Gy) tumors. However, HHP vaccination combined with RT failed to induce abscopal anti-tumor immune responses, namely those to non-irradiated tumors, and even partly abrogated those which were induced with RT plus anti-PD-1. In the latter group, the abscopal effects were accompanied by an elevated infiltration of CD8+ T cells, monocytes/macrophages, and dendritic cells. 3 × 8 Gy failed to induce abscopal effects in association with increased expression of immunosuppressive checkpoint molecules compared to 2 × 8 Gy. We conclude that HHP vaccines induce anti-tumor effects, but only if the tumor microenvironment was previously modulated by hypofractionated RT with not too many fractions, but failed to improve RT plus anti-PD-induced abscopal responses that are characterized by distinct immune alterations. Full article
Show Figures

Graphical abstract

Back to TopTop